CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 199 enrolled
Drug / intervention
Hydroxychloroquine Pilldrug
Likely dose
Hydroxychloroquine Pill 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04554979
NCT04554979N/ACompleted

Corona Virus (COVID-19) Disease Duration and Gastrointestinal Tract (GIT) Manifestations; Can be New Disease Severity Classification. A Pilot Egyptian Single National Center Experience

Cairo University·observational·Posted Sep 18, 2020·Updated Sep 22, 2020

In Brief

An observational study evaluating Hydroxychloroquine Pill for Covid19 and Diarrhea. Completed, enrolled 199 participants across 1 site.

Detailed Summary

The present study conducted to correlate symptoms not only constitutional and respiratory, but GIT as a principle presentation, with laboratory markers and COVID-19 severe acute respiratory syndrome (SARS-COV2) disease outcomes, as the duration of symptoms varies substantially between patients; the investigators undertook this study to determine the optimal time to predict COVID-19 outcomes based on real-time experience.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19, Diarrhea
CountriesEgypt
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedSep 18, 2020
Enrollment StartJun 1, 2020
Primary CompletionJul 15, 2020
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 5.8 years ago

Interventions

Hydroxychloroquine Pilldrug

hydroxychloroquine 400 mg twice daily first day and maintained on 200 mg twice daily for 6 days in mild cases and 10 days in moderate cases. Also they received anticoagulants, vitamin c and zinc. In case of secondary bacterial infection, empiric antibiotics are started